Patents by Inventor Cory M. Johannessen

Cory M. Johannessen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277482
    Abstract: The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 9, 2021
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Cory M. Johannessen, David J. Konieczkowski, Levi A. Garraway
  • Patent number: 11078540
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 3, 2021
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., BROAD INSTITUTE, INC.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Patent number: 10968484
    Abstract: The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 6, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Cory M. Johannessen, David J. Konieczkowski, Levi A. Garraway
  • Publication number: 20170268069
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 21, 2017
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20160024589
    Abstract: The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Cory M. Johannessen, David J. Konieczkowski, Levi A. Garraway
  • Publication number: 20150141470
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20130059851
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
    Type: Application
    Filed: March 9, 2011
    Publication date: March 7, 2013
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Levi A. Garraway, Cory M. Johannessen